Press release
Checkpoint Inhibitor Pipeline Drugs, Pioneering Pipeline Therapies, Regulatory Approvals, Clinical Trials, and Mechanism of Action by DelveInsight
Checkpoint Inhibitor Pipeline
Request for free sample page @ https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Checkpoint Inhibitors Pipeline Competitive Landscape Report
• Over 180+ checkpoint inhibitors companies are evaluating 250+ checkpoint inhibitors pipeline therapies in various stages of development, and their anticipated acceptance in the checkpoint inhibitors market would significantly increase market revenue.
• Various leading companies in the field of checkpoint inhibitors, such as BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, Alpine Immune Sciences, Arcus Biosciences, Elpiscience Biopharmaceuticals, TransCode Therapeutics, Checkpoint Therapeutics, Orum Therapeutics, Avacta, Exelixis, and others, are currently examining novel candidates for checkpoint inhibitor drugs in order to enhance the treatment landscape.
• Promising checkpoint inhibitor pipeline therapies in various stages of development include BCD-100, CBP501, BEBT-260, FAZ053, Envafolimab, SG 12473, HBM-9027, CA-170, Tislelizumab, Geptanolimab, BCN 176, PH-3861, Adebrelimab, M7824, IBI-310, AGEN-1181, YH-001, PEP07, V-158411, Prexasertib, GDC-0575, PH-762, BI 765063, SOL-578, SRA 737, IMP 10, VER250840, ALPN-202, Zimberelimab, ES101, ES019, TTX siPDL1, Cosibelimab, Research programme: PD-1-Cbl-b therapeutics, APL 502, APL-801, AVA 028, AVA 021, LR-19128 PD-L1 XT, XB-628, XB014, SHR 1701 and others.
• In April 2023, Enlivex Therapeutics Ltd. announced a clinical collaboration agreement with BeiGene. The Company entered into this collaboration to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for the treatment of patients with advanced-stage solid tumors, a part of the Company's ongoing Phase I/II clinical trial.
Request a sample and discover the recent advances in the checkpoint inhibitors market @ https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Checkpoint Inhibitors Overview
Checkpoint inhibitors are a type of immunotherapy. They obstruct proteins that prevent the immune system from attacking cancer cells. Cancer medications do not usually fit neatly into a specific form of treatment, and this is because certain medications function in multiple methods and belong to more than one class. Checkpoint inhibitors are frequently referred to as monoclonal antibodies or targeted treatments. The immune system protects humans from disease by killing germs and viruses, and t cells are the most common type of immune cell that achieves this.
Checkpoint inhibitors are drugs that suppress checkpoint proteins. They prevent proteins in cancer cells from pressing the stop button, and this activates the immune system, allowing T cells to locate and attack cancer cells. These medications inhibit the following checkpoint proteins: CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed cell death ligand 1). T cells express CTLA-4 and PD-1, and PD-L1 is found in cancer cells. These medications stimulate all immune cells, not just those that fight cancer. As a result, hyperactive T cells may have unintended consequences.
Find out more about FDA checkpoint inhibitors @ https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Checkpoint Inhibitors Pipeline Analysis: Drug Profile
BCD-100: BIOCAD
Prolgolimab (BCD-100), developed by BIOCAD, is a completely human monoclonal antibody with PD-1 receptor specificity. It is an immunoglobulin G1 with L234A/L235A mutations that result in reduced affinity for Fc receptors. It is Eastern Europe's first immune checkpoint inhibitor. In Russia, prolgolimab is already approved for the treatment of unresectable or metastatic melanoma. Prolgolimab is also being developed in combination with other medicines for the treatment of advanced NSCLC and cervical cancer as part of the Harmony clinical program. The drug is currently in Phase III development for the treatment of Non-Squamous Non-Small Cell Lung Neoplasm.
CBP501: CanBas Co., Ltd.
CanBas's CBP501 is a novel calmodulin-modulating peptide with a well-defined multimodal anti-tumor function. This mode of action leads to increased platinum influx into and cytotoxicity to tumor cells, specifically, immunogenic cell death of tumor cells, suppression of M2 macrophage activity, reduced populations of cancer stem cells, and reduced migration/invasion by and epithelial-to-mesenchymal transition (EMT) of tumor cells even with short-term exposure treatment. CBP501 also improves the efficacy of some immune checkpoint inhibitors when combined with cisplatin or carboplatin. In the CT-26 syngeneic mice model, CBP501 and a platinum drug combined with anti-PD1, anti-PDL1, or anti-CTLA4 inhibit tumor growth while increasing CD8 T cells and decreasing M2 macrophages at tumor locations. The drug is currently in a Phase II clinical trial for the treatment of Stage IV pancreatic cancer.
Checkpoint Inhibitors Pipeline Drugs:
• BCD-100: BIOCAD
• Envafolimab: 3D Medicines
• IBI310: Innovent Biologics
• Bintrafusp alfa: EMD Serono/Merck
• CA-170: Aurigene Discovery Technologies
• CBP501: CanBas Co., Ltd.
• Botensilimab: Agenus
• FAZ053: Laekna Therapeutics
• BEBT-260: BeBetter Med
• SG 12473: Hangzhou Sumgen Biotech
• HBM-9027: Harbour BioMed
• PH-3861: Phio Pharmaceuticals
Learn more about the checkpoint inhibitor drugs @ https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Checkpoint Inhibitors Competitive Landscape Report
• Coverage: Global
• Key Checkpoint Inhibitors Companies: BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine,Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, Alpine Immune Sciences, Arcus Biosciences, Elpiscience Biopharmaceuticals, and others
• Key Checkpoint Inhibitors Pipeline Therapies: BCD-100, CBP501, BEBT-260, FAZ053, Envafolimab, SG 12473, HBM-9027, CA-170, Tislelizumab, Geptanolimab, BCN 176, PH-3861, Adebrelimab, M7824, IBI-310, AGEN-1181, YH-001, PEP07, V-158411, Prexasertib, GDC-0575, PH-762, BI 765063, SOL-578, SRA 737, IMP 10, VER250840, ALPN-202, Zimberelimab, ES101, ES019, and others.
• Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive drugs assessment, Unmet Needs
Dive deep for rich insights into checkpoint inhibitor therapy; visit @ https://www.delveinsight.com/sample-request/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Checkpoint Inhibitors Pipeline Report Introduction
2. Checkpoint Inhibitors Pipeline Report Executive Summary
3. Checkpoint Inhibitors Pipeline: Overview
4. Marketed Checkpoint Inhibitors Drugs
4.1. Pembrolizumab: Merck
5. Checkpoint Inhibitors Clinical Trial Therapeutics
6. Checkpoint Inhibitors Pipeline: Late-Stage Products (Pre-registration)
7. Checkpoint Inhibitors Pipeline: Late-Stage Products (Phase III)
7.1. BCD-100: BIOCAD
8. Checkpoint Inhibitors Pipeline: Mid-Stage Products (Phase II)
8.1. CBP501: CanBas Co., Ltd.
9. Checkpoint Inhibitors Pipeline: Early-Stage Products (Phase I)
9.1. BEBT-260: BeBetter Med
10. Checkpoint Inhibitors Pipeline Therapeutic Assessment
11. Inactive Products in the Checkpoint Inhibitors Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
Trending Reports
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Minimal Residual Disease Market: https://www.delveinsight.com/infographics/minimal-residual-disease-market
• Critical Limb Ischemia Market: https://www.delveinsight.com/report-store/critical-limb-ischemia-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Ventricular Dysfunction Market: https://www.delveinsight.com/report-store/left-ventricular-dysfunction-pipeline-insight
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Allergic Rhinoconjunctivitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Kidney Transplant Rejection Market: https://www.delveinsight.com/report-store/kidney-transplant-rejection-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Adamantinoma Market: https://www.delveinsight.com/report-store/adamantinoma-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Non Alcoholic Fatty Liver Disease Nafld Market: https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-market
• Wound Closure Devices Market: https://www.delveinsight.com/report-store/wound-closure-device-market
• Chronic Rhinosinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-market
• Spinal Stenosis Market: https://www.delveinsight.com/blog/spinal-stenosis-devices-market-size
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-cit-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Cardiac Resynchronization Therapy Device Market: https://www.delveinsight.com/report-store/cardiac-resynchronization-therapy-market
• Malt Lymphoma Market: https://www.delveinsight.com/report-store/malt-lymphoma-market
Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+919650213330
https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Checkpoint Inhibitor Pipeline Drugs, Pioneering Pipeline Therapies, Regulatory Approvals, Clinical Trials, and Mechanism of Action by DelveInsight here
News-ID: 3342035 • Views: …
More Releases from DelveInsight Business Research
Peripheral T-Cell Lymphoma (PTCL) Market Analysis 2034 - Competitive Landscape, …
The Peripheral T-Cell Lymphoma (PTCL) Market across the 7MM was valued at approximately USD 680 million in 2020, and it is projected to experience steady growth by 2034.
Peripheral T-Cell Lymphoma (PTCL) Market Overview
As of 2023, the United States held the largest share of the PTCL therapeutics market within the 7MM, reaching a valuation of around USD 500 million, followed by Japan. Newly diagnosed patients are generally managed with anthracycline-based chemotherapy…
Nontuberculous Mycobacterial Infection Market Analysis 2034 - Competitive Landsc …
In 2023, the Nontuberculous Mycobacterial (NTM) Infections Market in the United States was valued at around USD 360 million, and it is projected to grow throughout the 2024-2034 forecast period.
Nontuberculous Mycobacterial Market Overview
The NTM infections market is anticipated to expand consistently between 2024 and 2034, fueled by advancements in diagnostics, the introduction of novel therapies, and growing disease awareness. The aging population, which is more susceptible to NTM infections, continues…
Lupus Nephritis Market Analysis 2034 - Competitive Landscape, Clinical Trials, M …
The Lupus Nephritis (LN) market was valued at approximately USD 1.8 billion in 2024 and is projected to expand steadily from 2025 to 2034, driven by the introduction of emerging therapies across the seven major markets (7MM).
Lupus Nephritis Market Summary
In Japan, the Lupus Nephritis market size was around USD 49 million in 2024, and it is anticipated to grow throughout the forecast period (2025-2034). Lupus Nephritis, a serious complication of…
Sjogren's Syndrome Market Outlook 2034 - Clinical Trials, Market Size, Medicatio …
Prominent Sjogren's syndrome companies include Rise Therapeutics, Bristol-Myers Squibb, Resolve Therapeutics, Novartis, Horizon Therapeutics, Dompe Farmaceutici, Horizon Therapeutics (Amgen), Sylentis, OSE Immunotherapeutics, Servier, Johnson & Johnson, and several others.
Sjogren's Syndrome Market Summary
In 2023, the Sjogren's syndrome market size across the seven major markets (7MM) was valued at approximately USD 1.9 billion and is expected to witness steady growth through 2034.
Sjogren's syndrome is an autoimmune disease that primarily disrupts the salivary…
More Releases for Checkpoint
Comparative Effectiveness of TIGIT Antibodies and Other Checkpoint Inhibitors
The comparative effectiveness of TIGIT antibodies and other checkpoint inhibitors is a topic of significant interest in the field of cancer immunotherapy. Immune checkpoint inhibitors have revolutionized cancer treatment by unleashing the immune system's ability to attack tumors. While PD-1 and CTLA-4 inhibitors have shown remarkable success, TIGIT antibodies offer a new approach with potentially complementary mechanisms.
Download Report
https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene
PD-1 inhibitors, such as pembrolizumab and nivolumab, block the PD-1 receptor on T…
Checkpoint Inhibitors Market Report 2024: Advancing Cancer Treatments
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Checkpoint Inhibitors Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $55.64 billion In 2028 At…
Checkpoint Inhibitors Competitive Landscape Report 2023
DelveInsight's, "Checkpoint Inhibitors Competitive Landscape 2023" report provides comprehensive insights about 180+ Checkpoint Inhibitors Companies and 250+ drugs in the Checkpoint inhibitors Competitive landscape. It covers the Checkpoint Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report
• DelveInsight's Checkpoint Inhibitors report depicts a robust space with 180+ Glioma…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an…
